Advice - reimburse mometasone/olopatadine nasal spray (Ryaltris®) for the treatment of allergic rhinitis
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse mometasone/olopatadine nasal spray (Ryaltris®) through the basic healthcare package. This medicinal product is intended for use in certain patients with allergic rhinitis. If the minister adopts our recommendation, mometasone/olopatadine nasal spray will be included in the Medicine Reimbursement System (GVS). Only then will this medicinal product be reimbursed from the basic health insurance package provided by health insurers.
Current status: advisory report sent to the minister
The National Health Care Institute has sent this advisory report to the Minister of VWS. The minister has the final decision on whether the medicinal product will be reimbursed under the basic health insurance package.
Mometasone/olopatadine nasal spray is intended for certain people with allergic rhinitis
Mometasone and olopatadine are the active ingredients in this medicinal product; the brand name is Ryaltris®. The medicinal product is a nasal spray.
The medicinal product can be used in people with allergic rhinitis, which is an inflammation of the nasal mucosa caused by seasonal allergens (such as the pollen of trees and grasses) and non-seasonal allergens (such as dust mites and pets). The manufacturer has requested reimbursement for adults and children aged 12 and older with moderate to severe nasal symptoms associated with allergic rhinitis.
Advice from the National Health Care Institute on reimbursing mometasone/olopatadine
The National Health Care Institute advises the minister of VWS to include mometasone/olopatadine nasal spray (Ryaltris®) in the basic health insurance package. The recommendation is to include the medicinal product on List 1B of the GVS.
For more information about the GVS and Lists 1A, 1B and 2, please visit the page on page ‘Reimbursement of extramural medicinal products (GVS)’.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicine, the insurance excess or whether you need to pay a personal contribution, please ask your health insurance provider.
How did the advice come about?
The National Health Care Institute advises the minister. The minister makes the final decision on whether the medication will be reimbursed under the basic health insurance package.
Explanation about the reimbursement of medicinal products
Mometasone/olopatadine nasal spray is an extramural medicinal product. ‘Extramural’ refers to medications for home use that can be obtained from a pharmacy with a physician’s prescription . These medications will only be reimbursed from the basic health insurance package if they are included in the GVS.